Project Grant HT94252410902

This $279,573 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation (OS) to reduce cigarette craving. The project will be conducted in two phases: Phase I will involve a crossover, micro-randomized controlled trial with 32 treatment-seeking smokers to refine the design...

This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) will provide $661,139 to The Ohio State University to test the use of oral nicotine pouches as an alternative to cigarette smoking among rural Appalachian adults. The study will evaluate whether oral nicotine pouches are more effective than nicotine replacement therapy (NRT) in helping this population reduce or quit smoking, which contributes to high cancer rates in the region. The...

This $310,319 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support the University of Louisville in conducting formative research to develop a motivation-based adolescent vaping typology to inform the development of tailored cognitive behavioral e-cigarette cessation interventions. The key objectives are to: 1) identify different types of adolescent e-cigarette users based on their motivations for use, 2)...

The National Cancer Institute (NCI) awarded a $257,415 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Research Foundation for the State University of New York (RF SUNY) to develop an AI-enhanced smartphone app-based intervention for adolescent e-cigarette cessation. The goal is to create a scalable, cost-effective intervention that uses AI-assisted user profiling and personalized content to help adolescents quit e-cigarettes. The 3-year project will...

This $602,315 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research to validate a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and use it to screen and test lung cancer prevention agents. The key objectives are to: 1) Define the human relevance of the in vivo NTCU/smoke mouse model of lung SCC premalignancy, 2) Validate an ex vivo precision cut lung slice approach to screening new prevention...

This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...

The National Cancer Institute (NCI) awarded a $452,540 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the use of electronic nose (e-nose) technology to predict and assess response to induction therapy, as well as identify recurrence, in patients with locally advanced non-small cell lung cancer. The research aims to develop a non-invasive approach using volatile organic...

The National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) awarded a $247,433 Project Grant to the University of Nebraska Medical Center (UNMC) for the "Parents Helping Parents for Youth Vaping Cessation (PHP-VX)" program. The goal of this feasibility study is to develop and test a parent-facilitated youth vaping cessation intervention, which will include online training sessions and weekly parent-to-parent support. A key sub-award of $34,102 was made to the...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $757,913 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct a randomized controlled trial assessing the efficacy and cost-effectiveness of providing Hispanic adults who smoke with a smoking cessation smartphone app (iCanQuit) alone versus the app combined with free nicotine replacement therapy. The goal is to determine whether the addition of free nicotine...